ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO113

A Self-Funded, Value-Based, Post-AKI Care Program: Predicted vs. Observed Outcomes

Session Information

  • AKI: Outcomes, RRT
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Solanki, Kaushal V., Geisinger Health, Danville, Pennsylvania, United States
  • Gotschal, Dolly Ann, Geisinger Health, Danville, Pennsylvania, United States
  • Chang, Alexander R., Geisinger Health, Danville, Pennsylvania, United States
  • Norfolk, Evan, Geisinger Health, Danville, Pennsylvania, United States
  • Singh, Gurmukteshwar, Geisinger Health, Danville, Pennsylvania, United States

Readmissions occur in 20% patients with Acute Kidney Injury (AKI), adding $20000 in healthcare costs. While post-AKI care improves outcomes,studies are limited to non-dialysis referred patients. As one of the earliest post-AKI clinics,we set up a self-sustaining multi-disciplinary post-AKI care program.


Target population/interventions were finalized by interviewing nephrologists,patients and AKI!Now Workgroup. Since May 2022,hospitalized adults with high-risk stage 2/3 AKI at Geisinger Medical Center were identified in real-time. Those eligible were provided inpatient AKI education, nurse coordinator services, flexible scheduling, non-face-to-face care and expedited nephrology visits. Follow-up was up to 90 days post-discharge. Observed vs Predicted (Grampian-Aberdeen model) 90-day rehospitalization/mortality risk were compared.


On screening 1198 patients,303 were eligible; 195 (64.4%, 5% on dialysis) were enrolled (Fig 1) and 154 have completed 90 days. More than 95% received direct or non-face-to-face nephrology care. Fig 2 shows predicted vs observed outcomes: 90-day rehospitalization/mortality was 30.2% vs a mean risk of 45.8%. Graphical pattern suggests steady benefit lending itself to a Difference-in-Difference estimation.


We developed a value-based comprehensive post-AKI care model showing improvement over predicted outcomes. Our approach allows quasi-experimental analysis and could be widely applicable.

Figure 2